Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulants.

Jack Hirsh1, Martin O'Donnell, Jeffrey I Weitz

  • 1Henderson Research Center, and McMaster University, Hamilton, Ontario, Canada. Jhirsh@thrombosis.hhscr.org

Blood
|June 12, 2004
PubMed
Summary

New anticoagulants, like oral direct thrombin inhibitors, offer alternatives to warfarin for preventing blood clots. Ximelagatran shows promise in large trials for venous thromboembolism and atrial fibrillation patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

A short history of anticoagulant therapy.

Thrombosis research·2026
Same author

In memory of Dr. Jeffrey Ginsberg.

Thrombosis research·2026
Same author

From bench to bedside: the untold story behind the clinical development of enoxaparin.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Anticoagulants: From chance discovery to structure-based design.

Pharmacological reviews·2025
Same author

Usual On-therapy Ranges of Drug Concentrations in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.

Thrombosis and haemostasis·2024

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiovascular Medicine

Background:

  • Existing anticoagulants (vitamin K antagonists, heparins) have limitations.
  • Development of novel anticoagulants targeting specific coagulation pathways is ongoing.
  • A need exists for oral anticoagulants to replace warfarin for long-term use.

Purpose of the Study:

  • To review emerging anticoagulant therapies targeting specific coagulation factors.
  • To highlight oral anticoagulants, particularly direct thrombin inhibitors like ximelagatran.
  • To discuss clinical trial progress for new anticoagulant agents.

Main Methods:

  • Review of current and investigational anticoagulant therapies.
  • Focus on agents targeting factor VIIa/tissue factor, factor Xa, activated protein C, and thrombin.
  • Evaluation of oral anticoagulants in clinical trials for thrombosis and cardioembolism prevention.

Main Results:

  • Several new anticoagulant classes are under clinical evaluation.
  • Oral direct inhibitors of factor Xa and thrombin are emerging.
  • Ximelagatran, an oral direct thrombin inhibitor, has completed large Phase 3 trials.

Conclusions:

  • Novel anticoagulants offer targeted approaches to thromboembolic disorders.
  • Oral anticoagulants like ximelagatran may fulfill the clinical need for warfarin alternatives.
  • Further research and clinical application of these agents are anticipated.

Related Experiment Videos